4.7 Article

An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-κB

Journal

CANCER LETTERS
Volume 396, Issue -, Pages 76-84

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.03.016

Keywords

Benzofuran-conjugated iridium(III) complex; STAT3; NF-kappa B; Prostate cells; Dual inhibitors

Categories

Funding

  1. Hong Kong Baptist University [FRG2/15-16/002]
  2. Health and Medical Research Fund [HMRF/14130522]
  3. Research Grants Council [HKBU/12301115, HKBU/204612, HKBU/201913]
  4. French National Research Agency/Research Grants Council Joint Research Scheme [A-HKBU201/12-Oligoswitch]
  5. Natural Science Foundation of China [21575121]
  6. Guangdong Province Natural Science Foundation [2015A030313816]
  7. Hong Kong Baptist University Century Club Sponsorship Scheme
  8. Interdisciplinary Research Matching Scheme [RC-IRMS/15-16/03]
  9. Science and Technology Development Fund
  10. Macao SAR [098/2014/A2]
  11. University of Macau [MYRG2015-00137-ICMS-QRCM, MYRG2016-00151-ICMS-QRCM, MRG044/LCH/2015/ICMS]
  12. National Natural Science Foundation of China [21628502]

Ask authors/readers for more resources

Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells. All complexes show the high stability and solubility in the biological system. In this study, an iridium(III) complex engages STAT3 and NF-kappa B to inhibit their translocation and transcriptional activities. Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects. Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer. (C) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available